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urprises of the Genome
nd “Personalized” Medicine*
li J. Marian, MD, FACC
ouston, Texas
he genome continues to fascinate and humble its enthusiasts.
ny major step in the ladder of scientific discoveries taken
oward understanding the genome is soon overshadowed by
ewer discoveries. The large monotonous macromolecule
hat Friedrich Miescher, the discoverer of deoxyribonucleic
cid (DNA), called the “nuclein,” has only 4 randomly
epeating letters (1). This apparent simplicity misled scien-
ists for about 75 years until the surprising discovery that the
randomly repeating nucleotides contained Johann Gregor
endel’s “elements of hereditary” (2). It was just as fasci-
ating to discover that the “elements of hereditary” com-
rised2% of over 3 billion nucleotide pairs in the genome.
he rest was considered “junk DNA.” Then we were
umbled to learn that there simply was no “junk DNA” but
hat signals were posted in every corner of the genome. The
iscovery of microribonucleic acids, transcribed from in-
rons and intergenic regions, and demonstration of their role
n regulating cardiac function are powerful evidence of the
ignificance of the “junk DNA” (3–5). Moreover, the
nformation conveyed by the genome is not restricted to its
ucleotide sequence but also comprises an extra layer of
omplexity imparted by the epigenetic mechanisms (6).
See pages 435, 444, and 449
The completion of the draft sequence of 2 sets of the
uman genome in 2001 (Human Genome Sequencing
onsortium and Celera Genomics) was a huge step on the
adder of scientific discoveries (7,8). Yet, the triumph soon
aced the challenge of deciphering the meaning of the
equence, i.e., annotation. Comparison of the draft se-
uence of the 2 genomes documented the abundance of
NA polymorphisms, primarily at the single nucleotide
evel. Since then, the number single nucleotide polymor-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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exGen Fund from the Greater Houston Community Foundation.hisms (SNPs) has increased to nearly 12 million. A
lethora of studies have utilized the existing databases to
orrelate phenotypes with genotypes. The approach primarily
as been SNP-centric, because until now SNPs were consid-
red to be the primary genetic determinants of the interindi-
idual variability in susceptibility to disease, response to treat-
ent (pharmacogenetics), and clinical outcomes.
The genome surprised us once again when Dr. J. Craig
enter’s DNA sequence—as a diploid genome sequence—was
eleased in September 2007 (9). The distinction merits clari-
cation, because the Human Genome Sequencing Consor-
ium assembly was a composite sequence of haploids derived
rom several individuals, and the Celera Genome was a
onsensus sequence derived from 5 individuals. Surprisingly,
4% of Venter’s annotated genes were heterozygous for one or
ore variants (9). Venter’s DNA sequence had 4.1 million
NA sequence variations of which one third were novel. This
s remarkable considering that there are already nearly 12
illion SNPs in the database. More astonishing was the
bundance of insertions, deletions, duplications and other
earrangements in Venter’s genome. Importantly, the non-
NP DNA variations involved 74% of the variant nucleotides.
he information changes the landscape and shifts the para-
igm from an SNP-centric to a genome-centric approach in
enetic studies of complex phenotypes. It is probably fair to
uggest that the genome of each individual is “private.”
The genome, through the information imprinted in its
NA sequence and beyond, is an important determinant of
iologic phenotypes. The magnitude of its contribution is
ontext dependent but by and large is a lion’s share of the
urden. However, genomic information, although crucial for
he development of the phenotype, is not usually complete.
he underlying extra complexity of a phenotype arises from
ntertwined dynamic and nonlinear interactions between the
enome—in the broader definition—and the host’s personal
nvironment. Therefore, biologic phenotypes, including all in
ealth and disease, are for the most part the products of the
enome interacting with environmental factors.
Advances in molecular genetic techniques have afforded
he opportunity to identify the genetic determinants of the
uman phenotype. Accordingly, the molecular genetics of
arious Mendelian disorders have been delineated (10). In
ontrast, our understanding of the molecular genetic basis of
omplex diseases has remained rudimentary. Genome-wide
ssociation study (GWAS) has raised considerable enthusi-
sm for detecting, without prior acknowledge, the suscepti-
ility alleles for complex traits such as coronary atherosclerosis
nd myocardial infarction (MI) (11–14). Unfortunately, the
rst set of GWAS was performed mostly in unmatched case
nd control subjects, and therefore the results are subject to the
onfounding effects of the covariates, such as the known risk
actors for coronary atherosclerosis and MI.
A much more restrictive approach to genetic studies of
omplex traits is the candidate gene approach, where associa-
ion of the phenotype with variants of a biologically plausible
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January 29, 2008:456–8 Editorial Commentene is analyzed. As in GWAS, the study design and robust
ata analysis are fundamental to gaining meaningful results. In
ll association studies, whether genome-wide or candidate-
ene, replication is considered to be an important step toward
alidation (15). In the present issue of the Journal, 3 studies
ave attempted to replicate and extend the results of an earlier
tudy showing a modest association between the nonsynony-
ous tryptophan719arginine (W719R) polymorphism in
IF6, encoding kinesin family member 6, and ischemic heart
isease (16). Likewise, the R variant of KIF6 was more
ommon in cases with MI than in control subjects in the
ARE (Cholesterol and Recurrent Events) study, the
OSCOPS (West of Scotland Coronary Prevention Study),
nd the WHS (Women’s Health Study) populations (17,18).
n a similar theme, albeit a completely different phenotype,
arriers of the R allele had a greater reduction in the coronary
vents rate in response to treatment with atorvastatin in the
ROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation
nd Infection Therapy: Thrombolysis in Myocardial
nfarction-22) study population, which was independent of
hanges in plasma low-density lipoprotein cholesterol
LDL-C) and C-reactive protein (CRP) levels (19).
These studies collectively raise interest in KIF6 as a
ossible candidate gene in susceptibility to MI, coronary
therosclerosis, and clinical response to statins. They have
onsiderable strengths, including the relatively large sample
ize of the study populations, carefully phenotyped partici-
ants, and concordant findings in separate datasets. None-
heless, the results at best should be considered provisional
ending validation through experimentation. The possibil-
ty of a spurious association should be considered. In a
andidate gene approach, first and foremost is to establish
he biologic plausibility of the candidate gene. Unfortu-
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Figure 1 Determinants of a Complex Phenotype
RNA  ribonucleic acid.ately, there is a paucity of information on KIF6, which
ncodes a member of the kinesin-9 family with a yet to be
efined function (20). The superfamily of motor protein
inesins is involved in the transportation of cellular cargo,
uch as protein complexes along the microtubules (20). The
hoices of KIF6 and the W719R SNP as the candidate gene
ere based on the results of an earlier study which reported
borderline association of the risk of ischemic heart disease
ith the W719R SNP (16). Like the previous study, the
resent studies also failed to establish the biologic plausi-
ility of KIF6 in susceptibility to coronary atherosclerosis
nd MI. Likewise, the results of the pharmacogenetic study,
hich showed genotype-dependent differences in the pri-
ary clinical outcome rate in the atorvastatin but not in the
ravastatin subgroups, require a plausible biologic explana-
ion. It is equally desirable to understand the basis for the
ndependence of the association between the clinical event
ates and the KIF6 genotypes from the response of the
lasma LDL-C and CRP levels to statin therapy. These
hortcomings are further compounded by the fact that KIF6
s not known to be expressed in the vasculature, the primary
ite of atherosclerosis. It is expressed at relatively low levels
n the brain, connective tissue, colon, eye, pharynx, skin, and
estes, organs not known to play a direct role in suscepti-
ility to atherosclerosis.
Thus, there is insufficient evidence for the biologic
lausibility of KIF6 as a candidate gene for risk of athero-
clerosis and MI or the response of clinical outcome to
tatins. Nevertheless, biologic plausibility, although an in-
egral part in the candidate gene approach, is only based on
xisting knowledge and alone is not sufficient to refute the
esults. Another common and largely arbitrary approach is
he pooling of 2 of the 3 genotypes in data analysis in the
It is a heart
It is a sick heart
es
nes
s
A
ional
ns  
nt
After
e of:l Gen
er Ge
enetic
oRN
nslat
catio
onme
edg
a
c
t
i
e
s
a
n
a
d
m
K
S
S
v
p
a
c
i
d
d
c
o
c
m
t
p
c
i
a
t
e
p
O
i
t
c
R
f
E
T
R
1
1
1
1
1
1
1
1
1
1
2
2
458 Marian JACC Vol. 51, No. 4, 2008
Editorial Comment January 29, 2008:456–8bsence of supportive biologic evidence. It increases the
hance of a spurious association and could be justified when
he risk allele is rare, the sample size of the study population
s small, and the supportive biologic evidence exists. How-
ver, W719R is a common SNP, and the sample sizes of the
tudy populations are large enough to afford independent
nalysis of the genotypes. The lack of a gene dose effect also
eeds biologic support and is a concern. Finally, the studies
re restricted to analysis of a single SNP with a yet-to-be-
efined function. The approach should have been comple-
ented with the comprehensive genetic screening of the
IF6 locus, which is known to contain several additional
NPs, including common and uncommon nonsynonymous
NPs. Despite these serious deficiencies, the results, if
alidated through experimentation, could portend a new
athway for the pathogenesis of coronary atherosclerosis
nd MI and possibly pharmacogenetics of statins.
The current SNP-centric approach to genetic studies of
omplex traits when complemented with mechanistic stud-
es could provide valuable insight into the pathogenesis of
isease and lead to identification of new prognosticators,
iagnostic markers, and therapeutic targets. The SNP-
entric approach, however, at best could encompass only
ne-fourth of the variant nucleotides in the genome (9). A
omplete paradigm shift from the current SNP-centric to a
ore comprehensive genome-centric approach is necessary
o capture the full potential of the genome. Given the rapid
ace of evolution of sequencing techniques, a genome-
entric approach is becoming a reality. Moreover, given the
ntricacy of factors that determine complex phenotypes, only
 comprehensive pluralistic approach that integrates all of
he constituents of the phenotype (Fig. 1), such as genomic,
pigenomic, transcriptomic, proteomic, and metabolomic
rofiles, could propel us toward “personalized” medicine.
therwise, the clinical utility of genetic association studies
n individualization of diagnosis, risk stratification, preven-
ion, and treatment will fall short of Dr. Koshland’s cha-
ha-cha theory of scientific discoveries (21).
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